Glimpazin-L 10 (Empagliflozin 10 mg + Linagliptin 5 mg Tablets):
Product Information
โ Brand Name: Glimpazin-L 10
โ Active Ingredients:
โ Empagliflozin 10 mg
โ Linagliptin 5 mg
โ Form: Tablets
Therapeutic Class
โ Antidiabetic agent (combination)
โ SGLT2 inhibitor + DPP-4 inhibitor
Indications
โ Treatment of type 2 diabetes mellitus
โ Improves glycemic control
โ Reduces risk of cardiovascular events
Dosage and Administration
โ Adult dose: 1 tablet once daily, in the morning
โ Take with or without food
Mechanism of Action
โ Empagliflozin:
โ Inhibits sodium-glucose cotransporter 2 (SGLT2)
โ Reduces glucose reabsorption in kidneys
โ Increases glucose excretion in urine
โ Linagliptin:
โ Inhibits dipeptidyl peptidase-4 (DPP-4)
โ Increases incretin hormone levels
โ Enhances insulin secretion and reduces glucagon levels
Benefits
โ Effective glycemic control
โ Reduced risk of cardiovascular events
โ Convenient once-daily dosing
โ Combination therapy for improved efficacy
Side Effects
โ Common:
โ Hypoglycemia (low blood sugar)
โ Urinary tract infections
โ Increased urination
โ Thirst
โ Headache
โ Less common:
โ Allergic reactions
โ Increased risk of genital mycotic infections
โ Increased risk of acute kidney injury
Contraindications
โ Hypersensitivity to empagliflozin or linagliptin
โ Severe kidney impairment (eGFR <30 mL/min/1.73 mยฒ)
โ End-stage renal disease (ESRD)
โ Dialysis
โ Pregnancy and lactation (caution advised)
Precautions
โ Monitor blood sugar, kidney function, and liver enzymes regularly
โ Inform doctor about concomitant medications
โ Caution in patients with:
โ Renal or hepatic impairment
โ History of pancreatitis
โ History of hypersensitivity reactions